Boehringer Ingelheim Phase III study now enrolling patients with progressive fibrosing lung diseases
- Category: Small Molecules
- Published on Monday, 20 March 2017 15:47
- Hits: 1157
- For the first time, patients with different fibrosing lung diseases will be included in one single clinical trial assessing the efficacy of nintedanib* as a potential treatment
- The PF-ILD clinical trial is the first in the field of fibrosing lung diseases to group patients based on the clinical behaviour of their disease, rather than the diagnosis
- In total, 600 patients will be included around the world
There are over 200 conditions that affect the tissue and space around the air sacs of the lungs (interstitium). These conditions are called interstitial lung diseases or ILDs.2 Based on clinical obervations there are groups of patients with ILD who independent from the classification of the ILD, exhibit a progressive fibrosing behaviour.3-6 The proposed terminology for describing this group of patients is PF-ILD. In these patients the disease appears to follow a course similar to IPF with worsening of respiratory symptoms, lung function, quality of life and ability to perform daily activites, as well as early mortality despite treatment.3-6
“This trial enrolls patients who have lung fibrosis of at least 10% by chest imaging that is getting worse by symptoms, physiology or imaging despite treatment,” said Kevin Flaherty, Coordinating Principal Investigator of the PF-ILD trial. “This trial is an innovative way to study a potential treatment for patients with progressive fibrosing lung diseases and is an important step in exploring the way fibrosis of the lung is treated and whether nintedanib could be an effective therapy.”
Nintedanib*, which is marketed as OFEV®, is approved for a rare lung disease called IPF, in which it has been shown to slow disease progression as measured by annual rate of decline in lung function.7-10 Building on the positive real-world clinical experience in IPF, the Phase III trial is now exploring whether nintedanib can effectively target the scarring in the lungs of patients suffering from other progressive fibrosing-ILDs.
“Boehringer Ingelheim is dedicated to advancing the understanding of fibrosing lung diseases where no or limited treatments exist,” said Dr Christopher Corsico, Chief Medical Officer Boehringer Ingelheim. “Our innovative PF-ILD trial is designed to include patients with fibrosing lung diseases who would not otherwise be eligible to participate in a clinical trial. This demonstrates the commitment of Boehringer Ingelheim to transform fibrosing interstitial lung diseases from fatal diseases to chronic, treatable ones.”
*Nintedanib is currently not approved for use in PF-ILD and its safety and efficacy has not yet been fully established.
About the study11
This double-blind, randomised, placebo-controlled study will evaluate the efficacy and safety of nintedanib 150 mg twice daily over 52 weeks in patients with PF-ILD. The primary endpoint is the annual rate of decline in forced vital capacity (FVC), a measure of disease progression. Other clinical evaluations include the absolute change from baseline in the King's Brief Interstitial Lung Disease Questionnaire (K-BILD), which measures the health-related quality of life of patients with ILDs to assess the impact of treatment. Other main secondary endpoints include time to first ILD exacerbation and overall survival. The study will include patients with PF-ILD with documented lung scarring on imaging (high-resolution computer tomography, HRCT), and whose lung function and respiratory symptoms or chest imaging have worsened despite treatment.
For more information please visit ClinicalTrials.gov.
Interstitial lung disease (ILD) encompasses a large group of over 200 lung disorders,2 but there is no widely accepted single classification. Based on clinical observations, there is a group of patients who, independent of their ILD diagnosis, at some point in time develop a progressive phenotpye. Based on their similar disease characteristics, including decline in lung function and early mortality,3-6 it is thought to be appropriate to group these conditions together, regardless of their ILD diagnosis. PF-ILD is the umbrella term for this group of patients.
About OFEV® (nintedanib)
OFEV®(nintedanib, is approved for the treatment of the rare lung disease IPF (idiopathic pulmonary fibrosis).7-10 OFEV® targets growth factor receptors, which have been shown to be involved in the mechanisms by which pulmonary fibrosis occurs. It is believed that nintedanib slows the decline in lung function by blocking the signalling pathways that are involved in fibrotic processes.8,12,13 In animal models, the anti-fibrotic activity of nintedanib was shown to be independent of the cause of the fibrosing lung disease.14
About Boehringer Ingelheim
Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates presently with a total of some 50,000 employees worldwide.
The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.
Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects through, for example, the initiative “Making More Health” while also caring for employees. Respect, equal opportunity and reconciling career and family form the foundation of mutual cooperation. The company also focuses on environmental protection and sustainability in everything it does.
In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 per cent of net sales.
For more information please visit www.boehringer-ingelheim.com